2019 / 01

Следующая статья
DOI: 10.24075/vrgmu.2018.095
Авторские права: © 2019 принадлежат авторам. Лицензиат: РНИМУ им. Н.И. Пирогова.
Статья размещена в открытом доступе и распространяется на условиях лицензии Creative Commons Attribution (CC BY).

ОБЗОР

Лабораторная диагностика как основа медицины 5П

С. Н. Щербо, Д. С. Щербо
Информация об авторах

Российский национальный исследовательский медицинский университет имени Н. И. Пирогова, Москва, Россия

Для корреспонденции: Сергей Николаевич Щербо
ул. Островитянова, д. 1, г. Москва, 117997; ur.liam@sobrehchs

Статья получена: 30.01.2019 Статья принята к печати: 13.02.2019 Опубликовано online: 14.02.2019
|
  1. Щербо С. Н., Щербо Д. С. Медицина 5П: Прецизионная медицина. Медицинский алфавит. Современная лаборатория. 2015; (4): 5–10.
  2. Щербо С. Н., Щербо Д. С. Персонализированная медицина: монография в 7 томах. т. 1 Биологические основы. Москва. РУДН. 2016, 224 с.; т. 2 Лабораторные технологии. Москва. РУДН. 2017, 437 с.
  3. Раскина К. В., Мартынова Е. Ю., Перфильев А. В. и др. От персонализированной к точной медицине. Рациональная фармакотерапия в кардиологии. 2017; 13 (1): 69–79.
  4. Щербо С. Н., Щербо Д. С. Медицина 5П: мобильное здравоохранение. Медицинский алфавит. Современная лаборатория. 2017; 4 (28): 5–11.
  5. Годков М. А. Лабораторная диагностика в эпоху научно- технической революции. Закат или рассвет? Лабораторная служба. 2017; 6 (3): 5–8.
  6. Щербо С. Н., Тогузов Р. Т. Тенденции развития современной лабораторной медицины (лекция). Клиническая лабораторная диагностика. 2009; (3): 25–32.
  7. Snyder M. iPOP and its role in participatory medicine. Genome Med. 2014; (6): 6.
  8. Roberts NJ, Vogelstein JT, Parmigiani G, et al. The predictive capacity of personal genome sequencing. Sci Transl Med. 2012; 4 (133): 133ra58.
  9. Katz J. The silent wold of doctor and patient. Baltimore: Johns Hopkins University Press; 1983.
  10. Jain KK. Personalized Medicine. Waltham: Decision Resoures Inc., MA, USA; 1998.
  11. Personalized Medicine Coalition (PMC). The Case for Personalized Medicine. 2010.
  12. U.S. Food and Drug Administration (FDA) Department of Health and Human Services, Paving the Way for Personalized Medicine: FDA Role in a New Era of Medical Product Development. [(accessed on 10 January 2014)]; Available from: http:// www.fda.gov/downloads/ScienceResearch/SpecialTopics/ PersonalizedMedicine/UCM372421.pdf.
  13. Ginsburg GS, Willard HF. Genomic and Personalized Medicine. Elsevier Science. 2012; 1350 p.
  14. Schleidgen S, Klingler C, Bertram T, et al. What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics. 2013; (14): 55.
  15. Nabipour I, Assadi M. Precision medicine, an approach for development of the future medicine technologies. ISMJ. 2016; (19): 167–84.
  16. O’Donnell PH, Danahey K, Jacobs M. Adoption of a clinical pharmacogenomics implementation program during outpatient care — initial results of the University of Chicago «1,200 Patients Project». Am J Med Genet C Semin Med Genet. 2014; (166C): 68–75.
  17. Juengist E, McGowan ML, Fishman JR, et al. From «Personalized» to «Precision» Medicine: The Ethical and Social Implications of Rhetorical Reform in Genomic Medicine. Hastings Cent Per. 2016; 46 (5): 21–33.
  18. Interlandi J. The Paradox of Precision Medicine. Sci Am. 2016; 314 (4): 24–25.
  19. Joyner MJ, Paneth N. Seven Questions for Personalized Medicine. JAMA. 2015; (55905): 2015–16.
  20. Collins FS, Varmus H. A New Initiative on Precision Medicine. N Engl J Med. 2015; (372): 793–95.
  21. Ziegelstein RC. Personomics. JAMA Intern. Med. 2015; (175): 888–89.
  22. Chochinov HM. Health care, health caring, and the culture of medicine. Curr Oncol. 2014; (21): e668–e669.
  23. Gupte AA, Hamilton DJ. Molecular Imaging and Precision Medicine. Cardiology. 2016; (133): 178–80.
  24. Mason-Suares H, Sweetser D, Lindeman N, et al. Training the Future Leaders in Personalized Medicine. J Pers Med. 2016; 6 (1): 1.
  25. Smoller J, Karlson E, Green R, et al. An eMERGE Clinical Center at Partners Personalized Medicine. J Pers Med. 2016; 6 (1): 5.
  26. Hricak H. Oncologic imaging: a guiding hand of personalized cancer care. Radiology. 2011; (259): 633–40.
  27. Le Tourneau C, Delord JP, Gonçalves A, et al. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. Lancet Oncol. 2015; (16): 1324–34.
  28. Garraway LA, Verweij J, Ballman KV. Precision oncology: an overview. J Clin Oncol. 2013; 31 (15): 1803–05.
  29. Bettegowda C, Sausen M, Leary R.J, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; (6): 224ra24.
  30. Malvezzi M, Bertuccio P, Levi F, et al. European cancer mortality predictions for the year 2014. Annals of Oncology. 2014; (25): 1650–56.
  31. Attard G, Beltran H. Prioritizing precision medicine for prostate cancer. Annals of Oncology. 2015; (26): 1041–42.
  32. Amin Al, Olama A, Benlloch S, et al. Risk analysis of prostate cancer in PRACTICAL, a multinational consortium, using 25 known prostate cancer susceptibility loci. Cancer Epidemiology, Biomarkers & Prevention. 2015; (24): 1121–29.
  33. Bancroft EK, Page EC, Castro E, et al. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: Results from the initial screening round of the IMPACT study. European Urology. 2014; (66): 489–99.
  34. Bechis SK, Otsetov AG, Ge R, et al. Age and obesity promote methylation and suppression of 5-alpha reductase 2—Implications for personalized therapy in benign prostatic hyperplasia. Journal of Urology. 2015; (194): 1031–37.
  35. Prakash K, Pirozzi G, Elashoff M, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays. Proceedings of the National Academy of Sciences of the United States of America. 2002; (99): 7598–603.
  36. Helfand BT, Hu Q, Loeb S, et al. Genetic sequence variants are associated with severity of lower urinary tract symptoms and prostate cancer susceptibility. Journal of Urology. 2013; (189): 845–48.
  37. Тофило М. А., Егорова Е. Н. МикроРНК, регулирующие адипогенез при сахарном диабете 2-го типа. Здоровье и образование в XXI веке. 2017; 19 (3): 108–11.
  38. Ahlqvist E, Storm P, Karajamaki A, et al. Novel subgroups of adult–onset diabetes and their association with outcomes: a data–driven cluster analysis of six variables. The Lancet Diabetes Endocrinology. 2018; 6 (5): 361–69.
  39. Дедов И. И., Титович Е. В., Кураева Т. Л. и др. Взаимосвязь генетических и иммунологических маркеров у родственников больных СД 1 типа. Сахарный диабет. 2008; (4): 46–50.
  40. Meigs JB, Cupples LA, Wilson PW. Parental transmission of type 2 diabetes: the Framingham Offspring study. Diabetes. 2000; (49): 2201–17.
  41. Shields BM, Longergan M, Dennis J, et al. Patient characteristics are associated with treatment response to second line glucose lowering therapy: a MASTERMIND study abstracts of 51st EASD annual meeting. Diabetologia. 2015; 58 (Suppl 1): S405.
  42. Chakera AJ, Steele AM, Gloyn AL, et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation. Diabetes Care. 2015; (38): 1383–92.
  43. Shields BM, McDonald TJ, Ellard S, et al. The development and validation of a clinical prediction model to determine the probability of MODY in patients with young-onset diabetes. Diabetologia. 2012; (55): 1265–72.
  44. Pearson ER, Pruhova S, Tack CJ, et al. Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia. 2005; (48): 878–85.
  45. Tan Lin, Jiang T, Tan Lan, et al. Toward precision medicine in neurological diseases. Ann Transl Med. 2016; 4. (6): 104.
  46. Bu L-L, Yang K, Xiong W.-X, et al. Toward precision medicine in Parkinson s disease. Ann Transl Med. 2016; 4 (2): 26.
  47. Vieta E. Personalised medicine applied to mental health: Precision psychiatry. Rev Psiquiatr Salud Ment. 2015; 8 (3): 117–18.
  48. Fernandes BS, Williams LM, Steiner J, et al. The new field of “precision psychiatry”. BMC Med. 2017; (15): 80.
  49. Stephan KE, Bach DR, Fletcher PC, et al. Charting the landscape of priority problems in psychiatry, part 1: classification and diagnosis. Lancet Psychiatry. 2016; 3 (1): 77–83.
  50. Insel TR. The NIMH Research Domain Criteria (RDoC) Project: precision medicine for psychiatry. Am J Psychiatry. 2014; 171 (4): 395–7.
  51. Andersson G, Titov N. Advantages and limitations of Internet-based interventions for common mental disorders. World Psychiatry. 2014; 13 (1): 4–11.
  52. Carvalho AF, Kohler CA, Brunoni AR, et al. Bias in peripheral depression biomarkers. Psychother Psychosom. 2016; 85 (2): 81–90.
  53. Marzano L, Bardill A, Fields B, et al. The application of mHealth to mental health: opportunities and challenges. Lancet Psychiatry. 2015; 2 (10): 9442–48.
  54. Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. Am J Psychiatry. 2014; 171 (12): 1278–86.
  55. Passalaqua G, Canonica GW. AIT (allergen immunotherapy): a model for the “precision medicine”. Clin Mol Allergy. 2015; (1): 24.
  56. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J. 2015; 8 (1): 17.
  57. Agusti A. The path to personalised medicine in COPD. Thorax. 2014; (69): 857–64.
  58. Fajt ML, Wenzel SE. Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care. J Allergy Clin Immunol. 2015; (135): 299–310.
  59. Zazzu V, Regierer B, Kuhn A, et al. IT Future of Medicine: from molecular analysis to clinical diagnosis and improved treatment. N Biotechnol. 2013; 30 (4): 362–65.